Delcath Expects Sales To Fall Below $35.1 Million Quarter Despite Raising Annual Outlook
Management expects holiday schedules and fewer new patient starts to slow the fourth quarter, even as its treatment network expands.
Delcath Systems, which treats cancers that start in or spread to the liver, raised its annual revenue outlook but forecast a fourth-quarter slowdown on Monday's earnings call. Chief Executive Officer Gerard Michel said holiday scheduling would remove close to two treatment weeks, helping explain why sales are expected to fall below the third quarter's $35.1 million.
Holiday Gaps And Fewer Starts
Chief Financial Officer Sandra put annual revenue guidance at $115 million to $117 million. The fourth-quarter range is $25.8 million to $27.8 million—below the latest quarter, though still approximately 25% to 34% above a year earlier. Management also expects at least 41% annual HEPZATO KIT volume growth, an 87% to 89% gross margin and positive adjusted earnings before interest, taxes, depreciation and amortization.
A Craig-Hallum analyst challenged the slowdown against approximately 0.6 new patient starts per treatment site per month in the third quarter. Michel said management examined last year's treatment schedules and this year's calendar to exclude days when it expects no treatments. “Could we be wrong? I'd love to be wrong,” he said.
Patient intake adds another limit. Last year's fourth quarter produced 0.3 to 0.35 new starts per site per month, and Michel said assuming the recent 0.6 pace would be aggressive. October results also fed into the forecast. “We're very comfortable with our guidance” was his assessment, expressed in the call as “we're very comfortable with our guidance.”
More Teams, More Treatment Capacity
The third-quarter results show what Delcath's expanding network can deliver. Revenue rose 71%, from $20.6 million a year earlier. HEPZATO KIT contributed $32.7 million, versus $19.3 million; its treatment volume grew 19% from the prior quarter and 72% from a year earlier. European CHEMOSAT revenue reached $2.4 million, versus $1.3 million.
HEPZATO KIT combines melphalan chemotherapy with a delivery system that isolates and filters blood from the liver. The FDA approved it on August 14, 2023, for adults whose uveal melanoma has spread to the liver. Trained cancer centers administer it; in Europe, Delcath sells the delivery system separately as CHEMOSAT.
Michel credited growth partly to physicians increasingly combining or sequencing the treatment with systemic therapy. He also cited patient requests, less competition from clinical trials and backup clinical teams secured through sales-force incentives. Extra perfusionists, anesthesiologists and interventional radiologists have increased hospital treatment capacity.
Company Executive Kevin Muir said growth was widespread across centers, with MD Anderson and Mass General increasing both team capacity and treatments. Delcath now has 33 active U.S. centers, including newly added University of Nebraska and AdventHealth. AdventHealth's network includes more than 50 hospitals, over 2,000 care sites and roughly 4 million unique patients annually; Muir said its physicians can direct patients into treatment centers.
Two additional centers have patients scheduled this month. Management expects at least one further activation to reach at least 36 centers by year-end, though Michel cautioned that appointments can be canceled. The company recorded its 1,000th U.S. commercial treatment during the quarter; University Hospital Southampton also performed its 500th CHEMOSAT procedure, led by Dr. Sachin Modi.
Profits Fund A Broader Pipeline
Net income reached $7 million, versus $0.8 million a year earlier, while operating cash flow rose to $8.2 million from $4.8 million. Delcath ended the quarter with $104.3 million in cash and investments and no debt. Gross margin increased to 89% from 87%, and adjusted earnings before interest, taxes, depreciation and amortization reached $11.5 million, versus $5.3 million.
Research spending rose to $11 million from $8 million as clinical staffing and trial activity increased. Selling, general and administrative costs reached $13.1 million, versus $10.3 million, with commercial expansion driving the increase. Sandra expects research spending to increase into 2027, while a nearly fully staffed commercial team across nine regions should require slower spending growth.
The mid-stage colorectal cancer trial is enrolling fast enough for management to expect an interim update around the second or third quarter of 2027, earlier than its previous expectation toward year-end. Breast cancer enrollment has been slower than anticipated; the first patient received treatment in July at the European Institute of Oncology in Milan, and multiple European and U.S. sites are recruiting.
Delcath plans to submit an application to begin a cholangiocarcinoma trial in early 2027. Pending FDA agreement, it also aims to complete preclinical work on an oxaliplatin-based treatment by mid-2027 to support a subsequent application. Michel said physicians' familiarity with oxaliplatin in colorectal and other gastrointestinal cancers is part of the rationale for that program.
Delcath's immediate forecast depends on both available treatment days and new patients arriving—not simply the number of centers open.
Sources
- Delcath Systems GAAP EPS of $0.17 beats by $0.25, revenue of $35.1M beats by $9.26M (DCTH:NASDAQ) | Seeking Alpha — seekingalpha.com
- Delcath Systems Reports Third Quarter 2026 Results and Business Highlights — businesswire.com